Literature DB >> 9798673

Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis.

C P Webb1, G A Taylor, M Jeffers, M Fiscella, M Oskarsson, J H Resau, G F Vande Woude.   

Abstract

Aberrations in Met-hepatocyte growth factor/scatter factor (HGF/SF) signaling have been implicated in the acquisition of tumorigenic and metastatic phenotypes. Here we show that murine NIH3T3 and C127 cells transformed by the Ras oncogene overexpress the Met receptor, resulting in enhanced HGF/SF-mediated responses in vitro including invasion through basement membrane. Accompanying the increase in Met in ras-transformed NIH3T3 cells, there is a decrease in endogenous HGF/SF expression as previously observed in cells exogenously overexpressing Met. However, subcutaneously grown tumors and experimental lung metastases derived from these cells express significantly higher levels of endogenous HGF/SF together with high levels of Met. These results suggest Met-HGF/SF signaling enhances tumor growth and metastasis of Ras-transformed NIH3T3 cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798673     DOI: 10.1038/sj.onc.1202135

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Authors:  Cristina Basilico; Anna Hultberg; Christophe Blanchetot; Natalie de Jonge; Els Festjens; Valérie Hanssens; Sjudry-Ilona Osepa; Gitte De Boeck; Alessia Mira; Manuela Cazzanti; Virginia Morello; Torsten Dreier; Michael Saunders; Hans de Haard; Paolo Michieli
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

3.  FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.

Authors:  Timothy G Whitsett; Shannon P Fortin Ensign; Harshil D Dhruv; Landon J Inge; Paul Kurywchak; Kerri K Wolf; Janine LoBello; Christopher B Kingsley; Jeffrey W Allen; Glen J Weiss; Nhan L Tran
Journal:  Clin Exp Metastasis       Date:  2014-04-08       Impact factor: 5.150

4.  Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.

Authors:  G A Gmyrek; M Walburg; C P Webb; H M Yu; X You; E D Vaughan; G F Vande Woude; B S Knudsen
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 5.  MET: roles in epithelial-mesenchymal transition and cancer stemness.

Authors:  Hye-Min Jeon; Jeongwu Lee
Journal:  Ann Transl Med       Date:  2017-01

6.  Role of Sphingosine Kinase 1 and S1P Transporter Spns2 in HGF-mediated Lamellipodia Formation in Lung Endothelium.

Authors:  Panfeng Fu; David L Ebenezer; Evgeny V Berdyshev; Irina A Bronova; Mark Shaaya; Anantha Harijith; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2016-11-18       Impact factor: 5.157

Review 7.  Genetic basis of human breast cancer metastasis.

Authors:  M T Debies; D R Welch
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

8.  Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase.

Authors:  K A Furge; D Kiewlich; P Le; M N Vo; M Faure; A R Howlett; K E Lipson; G F Vande Woude; C P Webb
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

9.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.

Authors:  Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

10.  A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.

Authors:  Yanan Yang; Marie Wislez; Nobukazu Fujimoto; Ludmila Prudkin; Julie G Izzo; Futoshi Uno; Lin Ji; Amy E Hanna; Robert R Langley; Diane Liu; Faye M Johnson; Ignacio Wistuba; Jonathan M Kurie
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.